Press release
Colorectal Cancer Market Poised for Steady Growth with a CAGR of 5% through 2034 | DelveInsight
The Colorectal Cancer market size is experiencing substantial growth across the 7MM. This growth is primarily driven by an aging population, the introduction of innovative therapies, such as KRAS and HER2 inhibitors, improved screening methods, and changes in dietary habits. Key companies, including Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Genentech, Merck, Takeda, Seagen Inc, Amgen, Pfizer, Roche, Genentech, GenFleet Therapeutics, InventisBio, BioNTec, and AbbVie, among others are driving innovations in treatment approaches, addressing unmet needs inthe colorectal cancer landscape.
According to the latest insights from DelveInsight's comprehensive report, "Colorectal Cancer Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/colorectal-cancer-crc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", the Colorectal Cancer market reached USD 13 billion across the 7MM in 2023, with projections indicating a steady CAGR of approximately 5% through 2034. This growth trajectory is supported by demographic shifts, including an aging population, changing dietary habits, and the introduction of innovative therapies, such as KRAS and HER2 inhibitors, alongside a deeper understanding of tumor biology and biomarker-driven treatment strategies.
The United States continues to dominate the Colorectal Cancer treatment market, accounting for approximately 40% of the total market share among 7MM in 2023. This is due to high adoption rates of premium-priced therapies, robust healthcare infrastructure, and favorable reimbursement frameworks.
Download the Colorectal Cancer market report to understand which factors are driving the Colorectal Cancer therapeutic market @ Colorectal Cancer Market Trends [https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
The report also analyzes historical and projected Colorectal Cancer epidemiology, segmented by total colorectal cancer incident cases, gender-specific cases, age-specific cases, tumor localization-specific cases, stage-specific cases, mutation-specific cases, and the total treated colorectal cancer cases in the 7MM.
Colorectal Cancer remains a significant global health concern, ranking as the third most commonly diagnosed cancer worldwide. In 2024, the incident cases of mCRC were approximately 294,500 cases in the 7MM. The Colorectal Cancer epidemiological data reveal that the United States accounted for approximately 30% of the total incident cases among 7MM in 2023.
DelveInsight's analysis further indicates that nearly 40% of the total incident cases of colorectal cancer in the US were classified as metastatic colorectal cancer, highlighting the urgent need for advanced treatment options for patients with late-stage disease. Additionally, age-specific data reveals a pronounced burden among individuals aged 65-84 years, emphasizing the correlation between aging populations and CRC incidence. Stage-specific distribution shows that localized colorectal cancer accounts for the highest proportion of cases, followed by regional, distant, and unknown stages, according to SEER data.
Moreover, the CRC Treatment Market Report provides insights into current treatment practices, emerging drugs, and the market share of individual colorectal cancer therapies. The current treatment landscape for colorectal cancer is characterized by a dynamic integration of traditional therapies, targeted treatments, and immunotherapy, reflecting significant advancements in precision oncology and molecular profiling.
Several targeted therapies, such as KRAZATI (Mirati Therapeutics), ENHERTU (AstraZeneca and Daiichi Sankyo), TUKYSA (Genentech/Seagen), KEYTRUDA (Merck), and FRUZAQLA (Takeda), among others, have revolutionized the CRC treatment market. While fluoropyrimidine-based chemotherapy regimens combined with biological agents like AVASTIN (bevacizumab) or ERBITUX (cetuximab) have long been standard options, there has been a recent shift toward biomarker-driven therapies targeting specific genetic alterations, such as KRAS, BRAF, and HER2 mutations.
Discover evolving trends in the Colorectal Cancer treatment landscape @ Colorectal Cancer Therapeutics Market [https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Recently, in January 2025, the FDA approved sotorasib (Amgen) in combination with panitumumab for KRAS G12C-mutated colorectal cancer. In December 2024, the FDA granted accelerated approval to BRAFTOVI (Pfizer) in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF mutation. Pfizer is currently seeking full approval based on the Phase III BREAKWATER Trial.
DelveInsight's analysis also indicates that the CRC therapeutic pipeline is rapidly evolving, driven by precision oncology and advancements in immunotherapy. Notable candidates, among others, include Divarasib (Roche/Genentech), GFH925 (GenFleet Therapeutics), D-1553 (InventisBio), Autogene cevumeran (BioNTech/Genentech), Onvansertib (Cardiff Oncology) and Telisotuzumab adizutecan (AbbVie), which targets the c-Met protein expressed in CRC cells along with a chemotherapy payload, a topoisomerase I inhibitor that kills cancer cells.
Recently, a phase 1 trial involving the immunotherapy drugs botensilimab and balstilimab has demonstrated remarkable promise for patients with microsatellite stable metastatic colorectal cancer (MSS mCRC), the most common form of colorectal cancer.
Another significant immunotherapy breakthrough involves JEMPERLI (GSK), which received FDA breakthrough therapy designation for locally advanced mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer in December 2024.
Unlock which Colorectal Cancer drug is expected to capture the largest market share in 7MM by 2032. Visit the Colorectal Cancer Market Insights [https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
As the Colorectal Cancer market continues to evolve, key trends include the rise of targeted therapies, particularly KRAS inhibitors for specific mutations, advancements in immunotherapy, and an increased focus on personalized medicine approaches that tailor treatments to individual patient profiles. The role of early detection methods in shifting treatment paradigms and improving outcomes remains central to addressing this significant public health challenge.
Table of Contents
1
Key Insights
2
Report Introduction
3
Executive Summary of Colorectal Cancer
4
Key Events
5
Colorectal Cancer Epidemiology and Market Forecast Methodology
6
Colorectal Cancer Market Overview at a Glance
7
Disease Background and Overview: Colorectal Cancer
8
Colorectal Cancer Treatment and Management
9
Colorectal Cancer Epidemiology and Patient Populationin the 7MM
10
Colorectal Cancer Patient Journey
11
Key Endpoints in Colorectal Cancer
12
Colorectal Cancer Marketed Therapies
13
Colorectal Cancer Emerging Therapies
14
Colorectal Cancer: Seven Major Market Analysis
15
Colorectal Cancer Unmet Needs
16
SWOT Analysis
17
KOL Views
18
Market Access and Reimbursement
19
Appendix
20
DelveInsight Capabilities
21
Disclaimer
22
About DelveInsight
Related Reports
Colorectal Cancer Pipeline Insight [https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Colorectal Cancer Pipeline Insight provides comprehensive insights about the Colorectal Cancer pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Colorectal Cancer companies, including Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc, Neogap Therapeutics AB, Criterium, Inc, Daiichi Sankyo, Inc, Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., and BioNTech SE, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=colorectal-cancer-market-poised-for-steady-growth-with-a-cagr-of-5-through-2034-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Colorectal Cancer Market Poised for Steady Growth with a CAGR of 5% through 2034 | DelveInsight here
News-ID: 3964069 • Views: …
More Releases from ABNewswire
A Gem of Joy ABA Breaks Barriers to Access with In-Home Therapy Services for Fam …
A Gem of Joy ABA offers in-home therapy services for Maryland families, breaking barriers to access and providing personalized support for children's development.
Maryland - A Gem of Joy ABA, a leading provider of autism therapy solutions, is making a transformative impact on families across Maryland by offering flexible and personalized in-home ABA Therapy. This innovative approach aims to break down barriers to care by delivering services directly to families' homes,…
Ontario Therapy Takes Action to Break Mental Health Stigma with DBT Therapy in B …
Ontario Therapy is expanding access to DBT therapy in Bradford, helping individuals overcome mental health challenges with effective, stigma-free support and coping strategies.
Bradford, ON - Ontario Therapy is taking significant steps to combat the stigma surrounding mental health by expanding access to Dialectical Behavior Therapy (DBT) in Bradford. With a mission to create more inclusive and supportive mental health care environments, Ontario Therapy is offering DBT therapy to help individuals…
Kelemer Brothers Helps Rockville Homeowners Save on Energy Bills with High-Effic …
Kelemer Brothers helps Rockville homeowners reduce energy bills with high-efficiency window replacements, improving insulation and home comfort.
Rockville, MD - Kelemer Brothers, a leading provider of window replacement services in Rockville, MD, is helping homeowners reduce their energy bills by offering high-efficiency Window replacement Rockville MD [https://www.kelemerbrothers.com/window-replacement-rockville-md/]. With the growing demand for energy-saving solutions, Kelemer Brothers is proud to provide cutting-edge window technology designed to enhance energy efficiency and comfort in…
Attorney Big Al's Proven Strategies Help Richmond, VA Residents Successfully Nav …
Attorney Big Al's proven strategies help Richmond, VA residents navigate personal injury claims with confidence, ensuring successful outcomes and fair compensation.
Richmond, VA - Attorney Big Al, a trusted name in personal injury law, continues to provide Richmond residents with effective legal representation designed to help clients recover compensation and peace of mind after accidents. With a record of proven strategies and years of experience, Attorney Big Al and his team…
More Releases for Colorectal
Metastatic Colorectal Cancer Therapeutics Market - Innovation in Motion: Elevate …
Newark, New Castle, USA: The "Metastatic Colorectal Cancer Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Metastatic Colorectal Cancer Therapeutics Market: https://www.growthplusreports.com/report/metastatic-colorectal-cancer-therapeutics-market/8685
This latest report researches the…
Potential Opportunities of Colorectal Cancer Therapeutics Market
The global colorectal cancer therapeutics market size is projected to reach USD 16.58 billion by 2026, owing to the rise in the prevalence of colorectal cancer worldwide. A report by Fortune Business Insights(TM) titled, "Colorectal Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Others), By Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and…
Colorectal Cancer Pipeline Therapeutic Review H1 2017
Colorectal Cancer Pipeline Review H1 2017 provides an overview of the Colorectal Cancer (Oncology) pipeline landscape. Colorectal cancer is cancer that starts in the large intestine (Colorectal). There is no single cause of colorectal cancer. Nearly all colorectal cancers begin as noncancerous (benign) polyps, which slowly develop into cancer.
For More on Colorectal Cancer Pipeline Review H1 2017 Report Inquire @
https://goo.gl/1HQ4Fn .
Report Description:
Pharmaceutical guide Colorectal Cancer - Pipeline Review H1…
US Colorectal Cancer Drug Pipeline Analysis
Among all the regions affected with colorectal cancer, the US would continue to account for a giant’s share owing to its huge population base. With regards to rates of increase, it is most likely that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions of the disease. According to estimates, approximately 55,000 people die…
Colorectal Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Colorectal Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in…
Colorectal Cancer Treatment Market- Global Outlook 2024
Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of the large intestine, which is the lower part of the body’s digestive system. The colon absorbs water and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which…
